1-Methylazepan-4-one | CAS:19869-42-2

We serve 1-Methylazepan-4-one CAS:19869-42-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-Methylazepan-4-one

Chemical Name:1-Methylazepan-4-one
CAS.NO:19869-42-2
Synonyms:1-Methylazepan-4-one
Hexahydro-1-methyl-4H-azepin-4-one
1-Methylhexahydroazepin-4-one hydrochloride
1-Methylazepan-4-one hydrochloride
 
Physical and Chemical Properties:
Boiling Point 196.4ºC at 760 mmHg
Melting Point 115-120ºC
Molecular Formula C7H14ClNO
Molecular Weight 163.645
Flash Point 67.2ºC
 
Specification:
Appearance:Yellow-brown powder
Assay:≥95.0%
Loss on drying:≤2.0%
Single impurity:≤1.5%
Total impurities:≤5.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Azelastine hydrochloride(CAS:79307-93-0).



Contact us for information like 1-Methylazepan-4-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Methylazepan-4-one hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Hexahydro-1-methyl-4H-azepin-4-one Use and application,1-Methylazepan-4-one technical grade,usp/ep/jp grade.


Related News: Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.’s governing body.2-Bromovaleric acid manufacturer Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.’s governing body.2-Chloro-4,6-dimethoxy-1,3,5-triazine supplier An active pharmaceutical ingredient (API) is a substance, or a mixture of ingredients, combined in the manufacture of a pharmaceutical or drug.2-Fluoro-5-methyl-3-nitropyridine vendor A system that allows Chinese citizens to enter South Korea’s Jeju Island without a visa is to be temporarily suspended.The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.